News | Heart Failure | July 07, 2022

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

Tenaya’s Precision Medicine Platform used to identify HDAC6 target using phenotypic screening and machine learning algorithms 

Tenaya’s Precision Medicine Platform Used to Identify HDAC6 Target Using Phenotypic Screening and Machine Learning Algorithms

Getty Images


July 7, 2022 — Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced the publication of preclinical research in the July 6 issue of Science Translational Medicine. The article, titled “Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy,” describes the discovery of histone deacetylase 6 (HDAC6) as a promising therapeutic target. These insights led to the development of the company’s lead small molecule candidate, TN-301, a highly selective HDAC6 inhibitor initially being developed for the potential treatment of heart failure with preserved ejection fraction (HFpEF). 

"While cardiovascular diseases remain the leading cause of death worldwide, innovation in therapeutic discovery has suffered from the challenge of identifying targets with validation in human tissue that can address underlying mechanisms of heart disease. The success of our approach using disease models based on human cells plus machine learning algorithms to discover promising new therapeutic targets for heart diseases provides reason to believe that this methodology may be broadly applicable to accelerating target and drug discovery of other disease-modifying therapies,” said Timothy Hoey, Ph.D., Chief Scientific Officer of Tenaya Therapeutics. “Research presented in this paper highlight the exquisite target selectivity and cardioprotective qualities of our HDAC6 inhibitors. We look forward to advancing TN-301, the first product candidate in our pipeline to be discovered and validated using this approach, into clinical studies.” 

Key Research Findings

The publication in Science Translational Medicine details Tenaya’s distinct Precision Medicine platform approach of applying phenotypic screening and deep learning to human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) disease models. Tenaya developed and validated a BAG3 knock-down human iPSC-CM model of dilated cardiomyopathy (DCM), a genetic cardiomyopathy that can lead to enlargement of the heart and heart failure in humans, for target identification and screening of novel cardiovascular disease candidates. In the BAG3-deficient human iPSC-CM models, HDAC6 inhibition was shown to protect against damage of the sarcomere, one of the basic building blocks of heart muscle present in all cardiomyocyte cells. Tenaya then developed a series of novel HDAC6 inhibitors through medicinal chemistry efforts that includes TYA-018 and TN-301, which are structurally and functionally similar. TYA-018 is used in Tenaya’s preclinical in vitro and in vivo studies of HDAC6 inhibition, while TN-301 is being advanced into clinical studies. 

To further validate the potential of HDAC6 inhibition, Tenaya translated its initial in vitro findings to a BAG3 cardiomyocyte knockout mouse model of DCM. BAG3 loss-of-function mutations have been linked to DCM and, in preclinical animal models, result in a steady loss of heart function leading to death from heart failure that simulates the progressive decline observed in human disease, providing a relevant model by which to study the results of targeted intervention.   

When evaluated in a BAG3 knock-out mouse model of DCM, HDAC6 inhibition with TYA-018: 

Demonstrated exquisitely selective enzyme inhibition, with greater than 2500-fold preference for HDAC6 over other members of the HDAC family 

Reduced sarcomeric damage, improved heart dilation, and conferred protection of left ventricular function from rapidly progressive decline. 

Enhanced cardiac energetics, mitochondrial membrane potential and reserve respiratory capacity, which contribute to maintaining improved heart function. 

Studying the mechanism of action of HDAC6 inhibition in these in vitro and in vivo DCM models provided additional insights that subsequently led to the discovery that HDAC6 inhibition may be highly effective in the setting of HFpEF with a multi-model mechanism of action. Based on extensive preclinical evaluation, Tenaya will seek to initially develop TN-301 for the potential treatment of HFpEF. Tenaya is on track to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2022. 

About TN-301 and HFpEF

TN-301 is a highly specific small molecule HDAC6 inhibitor initially being developed for the potential treatment of HFpEF. HFpEF accounts for approximately 50% of all heart failures, yet there are few proven treatment options. This disease involves systemic inflammation, left ventricular hypertrophy, fibrosis, and diastolic dysfunction resulting in high morbidity and mortality in affected individuals. In preclinical studies, TN-301 has been shown to have a multi-modal mechanism of action and to reverse many of the signs and symptoms of HFpEF in multiple relevant models, with evidence of reduced inflammation and fibrosis, overall improvement in metabolism, and improvements in left ventricular function and diastolic filling and pressures. Tenaya plans to submit an IND application to study TN-301 in human clinical studies to the FDA in the second half of 2022. 

About Tenaya’s Precision Medicine Platform

Tenaya’s Precision Medicine platform uses human iPSC-CMs as proprietary disease models combined with analysis of human genetics and the use of machine learning algorithms for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on insights from animal models to identify targets and to develop therapies intended for human heart disease. This platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner — including gene therapy, small molecules, and biologics — for both genetic and non-genetic forms of heart disease. 

For more information: www.tenayatherapeutics.com 


Related Content

News | Cardiovascular Clinical Studies

March 26, 2024 — Esperion announced the acceptance of three CLEAR (Cholesterol Lowering via Bempedoic acid, an ACL ...

Home March 26, 2024
Home
News | Cardiovascular Clinical Studies

March 25, 2024 — Abbott announced the first patient has been enrolled in the ENVISION investigational device exemption ...

Home March 25, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
News | Cardiovascular Clinical Studies

March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...

Home March 06, 2024
Home
News | Cardiovascular Clinical Studies

February 26, 2024 — More than 6 million Americans live with heart failure, and about half have an enlarged left ...

Home February 26, 2024
Home
News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
Subscribe Now